Eloxx Pharmaceuticals, Inc. Cash Flow Statement
ELOX|4 years of annual SEC 10-K data (FY2014-FY2025)
Covers operating cash flow, capital expenditures, free cash flow, share buybacks, and dividends paid across 4 fiscal years. All figures from audited SEC 10-K filings.
Eloxx Pharmaceuticals, Inc. used $14M in operating cash flow in FY2025.
Based on SEC 10-K filings.
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -40.59 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2025 | FY2016 | FY2015 | FY2014 |
|---|---|---|---|---|
| Net Income | -$17.1M | -$9.2M | -$6.1M | -$5.1M |
| Depreciation & Amortization | $113.0K | $349.7K | $293.6K | $258.0K |
| Operating Cash Flow | -$14.3M | -$4.9M | -$3.9M | -$4.4M |
| Capital Expenditures | - | $3.2K | $1.3K | $4.5K |
| Free Cash Flow | - | -$4.9M | -$3.9M | -$4.4M |
| FCF Margin | - | -2673.2% | -49928.5% | -56151.8% |